“…Indeed, the progressive nature of many forms of neuropsychiatric disease, including those linked to CACNA1C, is consistent with neurodegenerative processes that would be amenable to treatment with neuroprotective agents. 46 In this light, it is useful to note that P7C3 compounds have demonstrated protective efficacy in preclinical models of Parkinson disease, 24,[28][29] cognitive decline with aging, 31 amyotrophic lateral sclerosis, 23 traumatic brain injury, [25][26][27] peripheral nerve injury, 22 neurodegeneration-associated depression, 46 and now cell death associated with genetic susceptibility to mental illness. 17 It has recently been reported that P7C3 compounds enhance flux of the nicotinamide adenine dinucleotide (NAD) salvage pathway in normal mammalian cells, and also facilitate NAD recovery following doxorubicin exposure.…”